Sanofi, Regeneron up the ante on PD-1 I/O program by a billion dollars
With pivotal trial work well in hand and high hopes to start grabbing approvals for the world’s sixth PD-1/L1 checkpoint drug this year, Sanofi and its partners at Regeneron are boosting their development budget for cemiplimab to a minimum of $1.65 billion — a cool billion dollars more than they had pencilled into their development agreement three years ago.
Investigators at Sanofi $SNY and Regeneron $REGN have been bullish about carving out a place for themselves in one of the most competitive fields in immuno-oncology. As we reported recently, the Cancer Research Institute has found 164 PD-1/L1s in preclinical and clinical development as developers rush to compete in a market segment led by Merck and Bristol-Myers Squibb. There are three in Phase III — the program from Sanofi/Regeneron, PDR001 from Novartis and INCSHR-1210 from Incyte/Jiangsu Hengrui — and 9 in Phase II.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.